Device Master File and Technical Documentation for Drug–Device Combos Device Master File and Technical Documentation for Drug–Device Combos Context In today’s evolving landscape of pharmaceutical and biotechnology products, the integration of drugs with devices into combination products has become increasingly common. This necessitates a robust understanding of the regulatory frameworks governing these unique entities, especially in the context of regulatory affairs compliance. Combination products, which include drug–device combinations and biologics, present specific challenges that require tailored strategies for regulatory submission and approval. Legal/Regulatory Basis Drug–device combination products are regulated under different frameworks in the US, UK, and EU. Understanding these…

Post-Market Surveillance Expectations for Vaccines and Combination Products Post-Market Surveillance Expectations for Vaccines and Combination Products Context Post-marketing surveillance (PMS) serves as a critical aspect of regulatory oversight for vaccines and combination products within the scope of Pharmacovigilance (pharmacovig). As these products often exhibit unique safety and efficacy profiles post-approval, regulatory agencies such as the FDA, EMA, and MHRA emphasize rigorous PMS processes to ensure ongoing drug safety. This article outlines the expectations from key regulatory bodies regarding PMS, specifically for vaccines, combination products, and drug-device interactions. Legal and Regulatory Basis In the United States, the regulatory framework for PMS…

Cold Chain, Stability and Distribution Considerations for Vaccines Cold Chain, Stability and Distribution Considerations for Vaccines Context Vaccines are considered special product categories within the pharmaceutical industry due to their unique handling requirements, particularly concerning cold chain management. The regulatory landscape for vaccines includes stringent guidelines set forth by global authorities such as the FDA, EMA, and MHRA, alongside international standards like those established by the ICH. Understanding these regulatory frameworks is crucial for Regulatory Affairs (RA) professionals engaged in the development, manufacturing, and distribution of vaccines. Legal/Regulatory Basis The primary legal and regulatory documents governing vaccines include: 21 CFR…

Digital Tools for Monitoring Vaccine Safety and Effectiveness in Real Time Digital Tools for Monitoring Vaccine Safety and Effectiveness in Real Time In the context of evolving healthcare technologies and increasing focus on public health, it has become paramount for Regulatory Affairs (RA) teams to ensure rigorous oversight of vaccine safety and effectiveness. This article elucidates the regulations and guidelines surrounding digital tools utilized for monitoring vaccine safety and effectiveness, with an emphasis on navigating the complexities of special product regulatory pathways, particularly for products categorized under combination and advanced therapies. Regulatory Context Vaccines represent a critical component of public…

Global Harmonisation Challenges for Combination Product Regulations Global Harmonisation Challenges for Combination Product Regulations The evolution of healthcare technology has led to the emergence of combination products, which are defined as therapeutic and diagnostic products that combine drugs, devices, and/or biological products. The regulatory landscape for combination products is particularly complex, as it involves navigating multiple regulatory pathways across jurisdictions. This article serves as a comprehensive regulatory explainer manual for professionals in Regulatory Affairs, CMC, and Labelling teams within the pharmaceutical and biotech industries in the US, EU, and UK. It elaborates on relevant regulations, guidelines, and agency expectations regarding…

Borderline Decisions: When is a Product a Drug, Device or Combination? Borderline Decisions: When is a Product a Drug, Device or Combination? Context In the realm of pharmaceutical and biotech industries, the classification of products as drugs, devices, or combination products carries significant implications for regulatory compliance, development pathways, and market access. Understanding the nuances of these classifications is crucial for Regulatory Affairs (RA), Chemistry Manufacturing and Controls (CMC), and Labelling teams engaged in product development and commercialization in the US, UK, and EU. Regulatory agencies impose distinct requirements based on these classifications, making it vital for organizations to navigate…

Partnering with Device Manufacturers for Successful Combination Product Filings Partnering with Device Manufacturers for Successful Combination Product Filings Context Combination products represent a complex intersection of pharmaceuticals and medical devices, requiring a robust understanding of various regulatory frameworks. Navigating these regulations is critical for successful product development and market approval. Both regulatory compliance consulting and knowledge of special product regulatory pathways are essential for Regulatory Affairs (RA) professionals engaged in these efforts. As global markets evolve, companies developing combination products must collaborate effectively with device manufacturers while ensuring adherence to regulatory guidelines from agencies like the FDA, EMA, and MHRA….

Regulatory Strategies for Lifecycle Changes in Combination Products Regulatory Strategies for Lifecycle Changes in Combination Products The landscape of combination products is complex and evolving, necessitating a thorough understanding of regulatory frameworks to ensure compliance and facilitate approvals. In the realms of pharmaceuticals, biologics, and medical devices, combination products represent innovative therapies but simultaneously present unique regulatory challenges. This article serves as a comprehensive guide for Regulatory Affairs professionals navigating lifecycle changes in combination products, emphasizing the seamless integration of various disciplines within product development. Context Combination products are defined as therapeutic and diagnostic products that combine drugs, devices, and/or…

Risk Classification and Conformity Assessment for Drug–Device Platforms Risk Classification and Conformity Assessment for Drug–Device Platforms Context The intersection of pharmaceuticals and medical devices has led to the emergence of drug-device combination products, which pose complex regulatory challenges. These products can combine a drug with a device to enhance therapeutic effectiveness, leading to increased interest in regulatory and compliance consulting. Understanding the regulatory pathways and classification systems in the US, UK, and EU is crucial for manufacturers and regulatory affairs teams involved in the development and approval of these innovative products. Legal/Regulatory Basis The regulatory landscape for drug-device combinations varies…

Future Innovations: Wearables, On-Body Injectors and Smart Combination Products Future Innovations: Wearables, On-Body Injectors and Smart Combination Products The landscape of pharmaceutical and biotech product development is rapidly evolving, particularly with the advent of advanced therapies and special product categories such as wearables, on-body injectors, and smart combination products. This article aims to provide a comprehensive regulatory explainer manual for professionals in Regulatory Affairs, CMC, and Labelling teams focused on navigating the complexities of these innovative technologies. With a backdrop of international regulatory frameworks, particularly those from the FDA, EMA, and MHRA, this guide will elucidate key guidelines, requirements, and…